A Phase 2 interventional study of SDREGN2810 and SDREGN2810/ipi in Advanced Non-Small Cell Lung Carcinoma, sponsored by Regeneron Pharmaceuticals. Terminated at 31 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-03.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.
Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 23rd largest by enrollment, is one of 4 that started in 2018, is one of 19 in phase 2, and was the 3rd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Georgetown University · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
UNICANCER · Sites in France
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Austria, Estonia, France and 6 more countries
Ages 18+
Maia Biotechnology · Sites in Poland, Romania, Taiwan and 1 more country
Ages 18+
By country, each count listing its studies:
cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 6
First in 2017; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 61 across the 29 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 29 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals: 2 open now, 11 under way, 2 of them phase 3. Of 9 finished, 6 (67%) have results posted.
Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is the 16th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2018, is one of 7 in phase 2, and was the 5th registered.
Regeneron Pharmaceuticals’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2008.
3 of the studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06908304Phase 3Maia BiotechnologyA Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | 2027-07-31 |
| NCT06088771Icahn School of Medicine at Mount SinaiNeoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC | 2026-12-01 |
| NCT04253964Wake Forest University Health SciencesPilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Regeneron Pharmaceuticals’s 21 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to compare the objective response rate (ORR) of high dose cemiplimab (HDREGN2810) and standard dose cemiplimab plus ipilimumab combination therapy (SDREGN2810/ipi) to the ORR of standard dose cemiplimab (SDREGN2810) in the second-line treatment of patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC), in patients whose tumors express programmed cell death ligand 1 (PD-L1) in \<50% of tumor cells.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SDREGN2810
Drug: SDREGN2810/ipi
Drug: HDREGN2810
Standard dose intravenous (IV) infusion
Also known as: REGN2810, cemiplimab
Drug page: Cemiplimab
Combination therapy dose IV
Also known as: REGN2810, cemiplimab, ipilimumab
High dose IV
Also known as: REGN2810, cemiplimab
This study also gives Ipilimumab. No intervention listed here names it: that was found by reading the record.
Objective Response Rate (ORR) in Participants Whose Tumors Express Programmed Cell Death Ligand 1 (PD-L1) in <50% of Tumor Cells
ORR was defined as the number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of participants in the efficacy analysis set. BOR was defined as the best response recorded, as determined by a blinded Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) between the date of randomization and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever came first. CR was defined as the disappearance of all target lesions (Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm \[\<1 cm\]). PR was defined as having at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of randomization up to 41 months
Overall Response Rate
Overall Response Rate was defined as the number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of participants in the efficacy analysis set. BOR was defined as the best response recorded, as determined by a blinded Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) between the date of randomization and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever came first. CR was defined as the disappearance of all target lesions (Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm \[\<1 cm\]). PR was defined as having at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of randomization up to 41 months
Overall Survival (OS) in Participants With Tumor PD-L1 Expression Levels <50% of Tumor Cells
OS was defined as the time from randomization to the date of death due to any cause. A participant who lost to follow-up was censored at the last date that the participant was known to be alive. OS was measured using Kaplan-Meier method.
Time frame: Time from randomization to the date of death (up to 41 months)
Progression Free Survival (PFS) in Participants With Tumor PD-L1 Expression Levels <50% of Tumor Cells
PFS was defined as the time from randomization to the date of the first documented tumor progression, as determined by the IRC (based on RECIST 1.1 assessments) or death due to any cause, whichever occurred earlier. PFS was measured using Kaplan-Meier method.
Time frame: Time from randomization up to the date of the first documented tumor progression or death (up to 41 months)
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Resulting in Death
Adverse event (AE): any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE: AE with onset after start of treatment or with onset date before the treatment start date but worsening after the treatment start date. TEAEs included both serious and non-serious TEAEs. Number of participants with TEAEs, Serious TEAEs and TEAEs leading to death were reported.
Time frame: Up to 41 months
Number of Participants With Laboratory Test Abnormalities of Grade 2 or Higher Severity Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grading System
The laboratory measurements included hematology, chemistry, electrolytes and liver function. NCI-CTCAE was graded according to the following scale: Grade 1 (Mild): Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2 (Moderate): Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL); Grade 3 (Severe): Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4 (Life-threatening): Life-threatening consequences; urgent intervention indicated; Grade 5 (Death): Death related to AE.
Time frame: Up to 41 months
Due to early enrollment cessation, only 28 participants were randomized and 27 participants received study treatment in this study. One participant was randomized but not treated.
| Milestone | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W |
|---|---|---|---|
| Started | 8 | 11 | 9 |
| Treated | 8 | 11 | 8 |
| Completed | 0 | 3 | 1 |
| Not completed | 8 | 8 | 8 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Death | 3 | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Withdrawal of consent | 3 | 1 | 2 |
| Withdrew: Progressive disease | 1 | 2 | 1 |
| Withdrew: Other un-specified | 1 | 1 | 0 |
| Withdrew: Randomized, but never treated | 0 | 0 | 1 |
ORR was defined as the number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of participants in the efficacy analysis set. BOR was defined as the best response recorded, as determined by a blinded Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) between the date of randomization and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever came first. CR was defined as the disappearance of all target lesions (Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm \[\<1 cm\]). PR was defined as having at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of participants | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W |
|---|---|---|---|
| Objective Response Rate (ORR) in Participants Whose Tumors Express Programmed Cell Death Ligand 1 (PD-L1) in <50% of Tumor Cells | 0 (0.0 to 36.9) | 45.5 (16.7 to 76.6) | 0 (0.0 to 36.9) |
Overall Response Rate was defined as the number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of participants in the efficacy analysis set. BOR was defined as the best response recorded, as determined by a blinded Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) between the date of randomization and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever came first. CR was defined as the disappearance of all target lesions (Any pathological lymph nodes \[whether target or non-target\] must have reduction in short axis to \<10 mm \[\<1 cm\]). PR was defined as having at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| Percentage of participants | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W |
|---|---|---|---|
| Complete Response | 0 | 0 | 0 |
| Partial Response | 0 | 45.5 | 0 |
OS was defined as the time from randomization to the date of death due to any cause. A participant who lost to follow-up was censored at the last date that the participant was known to be alive. OS was measured using Kaplan-Meier method.
| Months | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W |
|---|---|---|---|
| Overall Survival (OS) in Participants With Tumor PD-L1 Expression Levels <50% of Tumor Cells | 5.1 (1.7 to NA) | NA (2.2 to NA) | 8.4 (1.4 to NA) |
PFS was defined as the time from randomization to the date of the first documented tumor progression, as determined by the IRC (based on RECIST 1.1 assessments) or death due to any cause, whichever occurred earlier. PFS was measured using Kaplan-Meier method.
| Months | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W |
|---|---|---|---|
| Progression Free Survival (PFS) in Participants With Tumor PD-L1 Expression Levels <50% of Tumor Cells | 2.0 (0.7 to 8.3) | 20.8 (1.2 to NA) | 1.8 (1.1 to 2.2) |
Adverse event (AE): any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE: AE with onset after start of treatment or with onset date before the treatment start date but worsening after the treatment start date. TEAEs included both serious and non-serious TEAEs. Number of participants with TEAEs, Serious TEAEs and TEAEs leading to death were reported.
| Participants | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W |
|---|---|---|---|
| Participants with any TEAE | 7 | 11 | 8 |
| Participants with any serious TEAE | 1 | 7 | 4 |
| Participants with any TEAE resulting in death | 0 | 2 | 1 |
The laboratory measurements included hematology, chemistry, electrolytes and liver function. NCI-CTCAE was graded according to the following scale: Grade 1 (Mild): Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2 (Moderate): Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL); Grade 3 (Severe): Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4 (Life-threatening): Life-threatening consequences; urgent intervention indicated; Grade 5 (Death): Death related to AE.
| Participants | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W |
|---|---|---|---|
| Hematology | 2 | 3 | 5 |
| Electrolytes | 3 | 3 | 1 |
| Liver Function | 2 | 3 | 1 |
| Chemistry | 1 | 1 | 0 |
Collected over From first dose up to 41 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cemiplimab 350 mg Q3W | 3/8 (37.5%) | 1/8 (12.5%) | 7/8 (87.5%) |
| Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | 3/11 (27.3%) | 7/11 (63.6%) | 11/11 (100%) |
| Cemiplimab 1050 mg Q3W | 4/8 (50%) | 4/8 (50%) | 8/8 (100%) |
| Event | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/8 | 3/11 | 0/8 |
| Brain stem embolismNervous system disorders | 0/8 | 0/11 | 1/8 |
| Cerebrovascular accidentNervous system disorders | 0/8 | 0/11 | 1/8 |
| HemiparesisNervous system disorders | 0/8 | 0/11 | 1/8 |
| BradypnoeaRespiratory, thoracic and mediastinal disorders | 0/8 | 0/11 | 1/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/8 | 0/11 | 1/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/8 | 0/11 | 1/8 |
| Acute myocardial infarctionCardiac disorders | 0/8 | 0/11 | 1/8 |
| Angina unstableCardiac disorders | 0/8 | 0/11 | 1/8 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/8 | 0/11 | 0/8 |
| Event | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W |
|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 4/8 | 3/11 | 3/8 |
| ConstipationGastrointestinal disorders | 3/8 | 2/11 | 1/8 |
| VomitingGastrointestinal disorders | 3/8 | 2/11 | 0/8 |
| HypothyroidismEndocrine disorders | 0/8 | 3/11 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 2/8 | 3/11 | 1/8 |
| PneumoniaInfections and infestations | 0/8 | 3/11 | 0/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/8 | 3/11 | 0/8 |
| Back painMusculoskeletal and connective tissue disorders | 1/8 | 3/11 | 1/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/8 | 3/11 | 2/8 |
| RashSkin and subcutaneous tissue disorders | 1/8 | 3/11 | 1/8 |
Safety analysis set (SAF) included all randomized participants who received any study drug; it is based on the treatment received (as treated).
| Age, Continuous(years) | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W | Total |
|---|---|---|---|---|
| Mean | 62.4 ± 7.91 | 68.5 ± 8.72 | 68.1 ± 12.08 | 66.6 ± 9.65 |
| Sex: Female, Male(Participants) | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W | Total |
|---|---|---|---|---|
| Female | 2 | 4 | 1 | 7 |
| Male | 6 | 7 | 7 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 7 | 6 | 19 |
| Unknown or Not Reported | 2 | 4 | 2 | 8 |
| Race (NIH/OMB)(Participants) | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 6 | 3 | 3 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 5 | 3 | 8 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 3 | 2 | 7 |
| Number of Participants with PD-L1 Tumor Expression Levels of ≥50% of Tumor Cells(Participants) | Cemiplimab 350 mg Q3W | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 1050 mg Q3W | Total |
|---|---|---|---|---|
| Count of participants | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Oct 2021, 40 months.
Results were first posted in Nov 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab
Carcinoma, Non-Small-Cell Lung →